Ellington Management Group’s Heron Therapeutics HRTX Stock Holding History

Ellington Management Group’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-18,600	Closed	-$218K	–	215
2020 Q1	$218K	Buy	+18,600	New	+$350K	0.05%	411
2018 Q3	–	Sell	-9,200	Closed	-$357K	–	579
2018 Q2	$357K	Buy	9,200 +400	+5%	+$12.7K	0.03%	241
2018 Q1	$243K	Sell	8,800 -2,000	-19%	-$45.4K	0.02%	665
2017 Q4	$195K	Buy	+10,800	New	+$176K	0.03%	493
2017 Q2	–	Sell	-10,400	Closed	-$156K	–	750
2017 Q1	$156K	Buy	+10,400	New	+$144K	0.01%	616
2015 Q3	–	Sell	-8,856	Closed	-$276K	–	785
2015 Q2	$276K	Buy	+8,856	New	+$167K	0.07%	467

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ellington Management Group's HRTX Position: Q2 2020 in Review

Ellington Management Group sold out of Heron Therapeutics (HRTX) in Q2 2020, closing a stake of 18,600 shares — an estimated $218K sold.

Ellington Management Group first reported a position in HRTX in Q2 2015 and held it in 6 quarters. The position peaked at $357K in Q2 2018. 190 funds tracked by Wall St. Rank hold HRTX as of Q2 2020.

Ellington Management Group reported no remaining Heron Therapeutics position as of Q2 2020 after selling out during the quarter.
Ellington Management Group sold 18,600 Heron Therapeutics shares in Q2 2020, an estimated $218K.
Ellington Management Group first reported a position in Heron Therapeutics in Q2 2015 and held it in 6 quarters.
Ellington Management Group's Heron Therapeutics position peaked at $357K in Q2 2018.
190 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2020.

Based on Ellington Management Group's 13F filing for Q2 2020, filed 17 Aug 2020.